Neurocrine Biosciences (NBIX) FCF conversion US GAAP (year values) |
|||||||||
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | LTM ? | 5 years average | |||
| FCF conversion, % | 168.8% | 122.0% | 86.9% | 87.1% | 112.3% | 94.3% | |||
| Changes by years, y/y, % | +22pp | -47pp | -35pp | +0pp | +25pp | 115% | |||
Neurocrine Biosciences. FCF conversion, %
Neurocrine Biosciences. FCF conversion, changes, pp
Neurocrine Biosciences (NBIX) FCF conversion US GAAP (quarter values) |
||||||||
| FY2025Q3 | FY2025Q4 | FY2026Q1 | FY2026Q2 | FY2026Q2 | LTM ? | |||
| FCF conversion, % | 71.6% | 166.0% | 70.7% | 67.7% | 94.3% | |||
| Changes by years, y/y, % | -7pp | +37pp | -102pp | -54pp | +14pp | |||
| Changes by quarters, q/q, % | +18pp | +94pp | -95pp | -71pp | ||||